PSMAddition Trial of Upfront Lutetium-177-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer - Andrew Armstrong

AIMode News Desk · curated summary

August 12, 20261 min readHealth

Automated news aggregation. Headlines and summaries are gathered from public feeds; see our editorial standards for sourcing, corrections, and AI-assist disclosure.

Related coverage: PSMAddition Trial of Upfront Lutetium-177-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer - Andrew Armstrong UroToday

About this story

This story was aggregated from UroToday. Headlines, summaries, and links are gathered automatically from public RSS feeds for your convenience.

Read the full story →

For agents:JSON record OpenAPI WebMCP llms.txt

More in Health

Health

Why Experts No Longer Recommend the BRAT Diet for Diarrhea and Nausea

Related coverage: Why Experts No Longer Recommend the BRAT Diet for Diarrhea and Nausea The New York Times The BRAT Diet Has Been a Go-To for Years. Experts Say It's Not Enough WBKR BRAT diet: Helping to keep nausea and diarrhoea at bay Bona Magazine

The New York Times · 1 hour ago

Health